Product Details
Place of Origin: China
Brand Name: Sunshine
Certification: ISO,COA
Model Number: 56211-40-6
Payment & Shipping Terms
Minimum Order Quantity: Negotiation
Price: Negotiation
Packaging Details: Bag,Drum
Delivery Time: 7-15 days
Payment Terms: L/C, D/A, T/T, Western Union
Supply Ability: TON
CAS NO:: |
56211-40-6 |
Appearance:: |
Crystalline Solid |
Molecular Formula:: |
C16H20N4O3S |
Molecular Weight:: |
348.42000 |
EINECS NO:: |
637-197-3 |
MDL NO:: |
MFCD00866166 |
CAS NO:: |
56211-40-6 |
Appearance:: |
Crystalline Solid |
Molecular Formula:: |
C16H20N4O3S |
Molecular Weight:: |
348.42000 |
EINECS NO:: |
637-197-3 |
MDL NO:: |
MFCD00866166 |
Product Description:
Product Name: Torasemide CAS NO: 56211-40-6
Synonyms:
N-(Isopropylcarbamoyl)-4-(m-tolylamino)pyridine-3-sulfonamide Torasemide;
TorseMide(DeMadex);
TorseMide API;
Chemical & Physical Properties:
Appearance: Crystalline solid
Assay :≥99.00%
Density: 1.283 g/cm3
Melting Point: 163-164℃
Refractive Index: 1.594
Storage Condition: Store in original container in a cool dark place.
Water Solubility: Soluble
Safety Information:
RTECS: UT7938000
Safety Statements: S26; S37/39
HS Code: 2935009090
Risk Statement: R36
Hazard Code: Xi
Torsemide is a pyridine-sulfonyl urea type loop diuretic.Target: OthersTorasemide is a pyridine-sulfonylurea type loop diuretic mainly used in the management of edema associated with congestive heart failure. It is also used at low doses for the management of hypertension. Torsemide significantly reduced total HF readmissions (relative risk [RR]: 0.41, 95% CI: 0.28-0.61, p < 0.0001) and HF readmissions (RR: 0.53, 95% CI: 0.33-0.84, p = 0.008) as well as CV readmissions (RR: 0.77, 95% CI: 0.60-0.98, p = 0.03) in patients with "at least 1 readmission." Torsemide caused a 14% reduction in all-cause mortality (RR: 0.86 [0.53-1.39], p = 0.54). Torsemide significantly reduces HF and CV-related hospital readmissions in systolic HF. Furthermore, torsemide is associated with a trend in reducing all-cause mortality . Torsemide has several characteristics that make it suitable for treatment of advanced heart failure including longer half-life, increased potency of diuretic action, and anti-aldosterone effects. This case report details the administration of torsemide in 3 dogs with advanced heart failure and apparent furosemide resistance .
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.